Healthcare Companies Report Stock Price Movement, Conference Call Schedules, Study Results, and Presentations - Research Report on Merck, Keryx Biopharma, Pacira, Ligand Pharma, and Dyax

Editor Note: For more information about this release, please scroll to bottom

Jan 10, 2014, 08:00 ET from Analysts' Corner

NEW YORK, January 10, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Merck & Co. Inc. Research Report

On January 6, 2014, Merck & Co. Inc. (Merck) announced that it will conduct its Q4 2013 sales and earnings conference call with institutional investors and analysts, on February 5, 2014, at 8:00 a.m. EST. According to the Company, Merck's executives will provide an overview of the Company's quarterly performance, during the call. Additionally, the Company stated that interested parties may access a live audio webcast of the call via Merck's website. Merck stated that a replay of the webcast will also be made available on its website on the same day at 11:00 a.m. EST for 12 months. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

--

Keryx Biopharmaceuticals Inc. Research Report

On January 7, 2014, Keryx Biopharmaceuticals Inc. (Keryx Biopharmaceuticals) announced that its CEO, Ron Bentsur, will represent the Company at the upcoming 32nd Annual J.P. Morgan Healthcare Conference, to be held from January 13 to January 16, 2014 in San Francisco. According to the Company, Mr. Bentsur's presentation is scheduled to be held on January 15, 2014, at 8:30 a.m. PT. Additionally, the Company stated that a live audio webcast of Mr. Bentsur's presentation will be accessible via Keryx Biopharmaceuticals' website under the Media section. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/27d2_KERX

--

Pacira Pharmaceuticals Inc. Research Report

On January 7, 2014, Pacira Pharmaceuticals Inc. (Pacira) announced results from the IMPROVE study in laparoscopic colectomy, which were published in the January 2014 issue of Current Therapeutic Research. According to the Company, the study evaluated 82 patients who underwent laparoscopic colectomy, a minimally invasive surgery to remove all or part of the colon using several small incisions in the abdomen. Commenting on the release, Dave Stack President, CEO and Chairman of Pacira, said, "There are millions of laparoscopic inpatient procedures performed annually in the United States, with the goal of reducing postsurgical pain and speeding patient recovery. This study has successfully demonstrated that even in minimally invasive procedures, EXPAREL makes a strong positive impact on both opioid use and hospital economics. The results of this and all of the IMPROVE studies underscore the value of EXPAREL, not only as an effective and long-lasting non-opioid analgesic, but also as an integral component of a hospital or provider's efforts to improve both the patient recovery experience and hospital economics." The Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c0aa_PCRX

--

Ligand Pharmaceuticals Incorporated Research Report

On January 7, 2014, Ligand Pharmaceuticals Incorporated's (Ligand Pharmaceuticals) stock gained 3.36% closing the day at $53.27. Ligand Pharmaceuticals shares advanced 3.40% over the past three-day trading period, compared to the Dow Jones Industrial Average Index which gained 0.54% during the same three-day trading period. The Full Research Report on Ligand Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3b8d_LGND

--

Dyax Corp. Research Report

On January 7, 2014, Dyax Corp.'s (Dyax) stock reflected an increase of 3.03%, closing the day at $7.82. During the past three-day trading session, the Company's stock edged up 2.89%, compared to the Nasdaq Composite Index which gained 0.24% over the same trading period. The Full Research Report on Dyax Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/58ae_DYAX

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner